View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2021

NIH to enter Phase II of Covid-19 biomarker development contract

The National Institutes of Health (NIH) unit National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) are set to enter Phase II of a multi-phase contract to advance physIQ’s artificial intelligence (AI)-based digital biomarker development for Covid-19.

The National Institutes of Health (NIH) unit National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) are set to enter Phase II of a multi-phase contract to advance physIQ’s artificial intelligence (AI)-based digital biomarker development for Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NCI and NIBIB exercised their option to enter the phase, which brings the total contract to $6.6m.

Being developed to address the fast decompensation of high-risk Covid-19 patients, the tool collects and assesses continuous physiologic data, which can potentially offer early clinical indicators of Covid-19 decompensation.

In Phase I of DeCODe study, physIQ enrolled and analysed 400 high-risk Covid-19 patients in ten weeks.

Using machine learning, the Covid-19 digital biomarker was developed and tested and is based on Phase I data.

In partnership with University of Illinois Hospital and Health Sciences System (UI Health), the DeCODe project will develop an early warning system that enables providers to intervene if the condition of a Covid-19 patient who is clinically surveilled from home is worsening.

Continuous multi-parameter vital signs and physiological features were used to establish a targeted biomarker or Covid-19 Decompensation Index (CDI) for worsening Covid-19.

physIQ chief science officer Stephan Wegerich said: “Using Phase I data, we developed and tested a preliminary digital biomarker, using state of the art machine learning algorithms that take advantage of our extensive library of wearable biosensor analytics as inputs.

“Furthermore, we were able to demonstrate performance levels that far exceeded our target performance criterion. We are looking forward to further validation in Phase II.”

The company noted that Phase II will start this month and enrol 1,200 patients for validating the digital biomarker.

Furthermore, in the validation phase, physIQ will enrol ambulatory Covid-19 patients and analyse the digital biomarker’s ability in predicting decompensation severity remotely.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network